激光间质热疗用于新发与复发脑膜瘤:一项前瞻性与回顾性病例系列研究
八家美国医院通过前瞻性多中心注册与回顾性入组,纳入20例接受激光间质热疗(LITT)的新发(6例)或复发(14例)脑膜瘤成人患者,30天并发症率为10%,中位随访1.3年,1年局部控制率55.3%、无进展生存率48.4%、总生存率86.3%。
要点
- 20例脑膜瘤患者接受LITT,其中新发6例、复发14例,复发次数1至12次。
- 30天并发症率10%(2/20),其中1例为暂时性并于术后缓解。
- 1年局部控制率55.3%、无进展生存率48.4%、总生存率86.3%。
核心结论
- 该队列研究支持LITT用于脑膜瘤的安全性。
- LITT可为尤其剩余治疗选择有限的多复发脑膜瘤患者提供一种急需的治疗选择。
研究设计与样本
- 八家美国医院参与的前瞻性多中心注册(LAANTERN)并补充回顾性入组的队列研究。
- 共纳入20例接受LITT治疗的脑膜瘤成人患者,其中前瞻性12例、回顾性8例。
- 新发肿瘤6例,复发肿瘤14例,复发次数范围为第1次至第12次。
- 20%的患者(4/20)已用尽所有其他治疗选择。
- 中位随访时间1.3年。
主要发现
- 30天并发症率为10%,并发症率10%(2/20),其中1例并发症为暂时性并于术后缓解。
- 新发脑膜瘤中三分之一(2/6)、复发脑膜瘤中一半(7/14)在随访期间出现疾病进展。
- 1年估计局部控制率、无进展生存率和总生存率分别为55.3%、48.4%和86.3%。
- 在12例消融覆盖率≥91%的患者中,1年估计局部控制率为61.4%。
临床怎么用
- 原文结论指出该队列研究支持LITT用于该肿瘤类型的安全性。
- 原文结论指出LITT可为尤其剩余替代方案有限的多复发脑膜瘤患者提供一种急需的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Meningiomas are the most common primary brain tumors in adults and a subset are aggressive lesions resistant to standard therapies. Laser interstitial thermal therapy (LITT) has been successfully applied to other brain tumors, and recent work aims to explore the safety and long-term outcome experiences of LITT for both new and recurrent meningiomas. The authors' objective was to report safety and outcomes data of the largest cohort of LITT-treated meningioma patients to date. METHODS: Eight United States-based hospitals enrolled patients with meningioma in the Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) prospective multicenter registry and/or contributed additional retrospective enrollments for this cohort study. Demographic, procedural, safety, and outcomes data were collected and analyzed using standard statistical methods. RESULTS: Twenty adult patients (12 prospective and 8 retrospective) with LITT-targeted meningiomas were accrued. Patients underwent LITT for new (6 patients) and recurrent (14 patients) tumors (ranging from the 1st to 12th recurrence). The 30-day complication rate was 10%. Twenty percent of patients (4/20) had exhausted all other treatment options. Median length of follow-up was 1.3 years. One-third of new (2/6) and one-half of recurrent (7/14) meningiomas had disease progression during follow-up. One-year estimated local control (LC), progression-free survival, and overall survival rates were 55.3%, 48.4%, and 86.3%, respectively. In the 12 patients who had ≥ 91% ablative coverage, 1-year estimated LC was 61.4%. The complication rate was 10% (2/20), with 1 complication being transient and resolving postoperatively. CONCLUSIONS: This cohort study supports the safety of the procedure for this tumor type. LITT can offer a much-needed treatment option, especially for patients with multiply recurrent meningiomas who have limited remaining alternatives.
引用
- Chiang VL, Pugazenthi S, Leidig WA, et al. Laser interstitial thermal therapy for new and recurrent meningioma: a prospective and retrospective case series. J Neurosurg. 2024. PMID: 38457795. doi:10.3171/2023.12.JNS231542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。